Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
Portfolio Pulse from
Outlook Therapeutics announced preliminary topline results from the NORSE EIGHT clinical trial for ONS-5010, a treatment for wet AMD. The company plans to resubmit its BLA application in early 2025.
November 27, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Outlook Therapeutics announced preliminary results from the NORSE EIGHT trial for ONS-5010, a treatment for wet AMD. The company plans to resubmit its BLA application in early 2025.
The announcement of preliminary results from a key clinical trial is a significant milestone for Outlook Therapeutics. The plan to resubmit the BLA application in early 2025 indicates progress towards potential market approval in the US, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100